Clinical Trials
A long-acting amylin-mimicking peptide best known as half of Novo Nordisk's CagriSema combo. Works alongside GLP-1 drugs to suppress appetite even further.
Blood Sugar & Insulin Regulation
Research
The natural gut hormone that Ozempic and Wegovy are modeled on. Your body already makes it — it just breaks down in minutes, which is why drug versions had to be re-engineered to last longer.
Research Phase
A dual GLP-1/glucagon receptor agonist approved in China for weight management, combining appetite suppression with increased energy expenditure.
Research
A peptide made inside your own mitochondria that mimics the metabolic benefits of exercise — improving energy and blood sugar control.
Clinical Trials
An experimental triple-hormone injection from Eli Lilly showing the biggest weight-loss results of any drug tested so far. Not yet approved — still in late-stage trials.
FDA Approved
The FDA-approved GLP-1 behind Ozempic and Wegovy. Reduces appetite, blood sugar, and heart disease risk.
FDA Approved
An FDA-approved weekly injection for diabetes and weight loss. Delivers the strongest results of any approved weight-loss medication to date.